BioMmune Announces Results of Initial UBC Work Program
2014年3月3日 - 11:00PM
Marketwired
BioMmune Announces Results of Initial UBC Work Program
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Mar 3, 2014) -
BioMmune Technologies Inc., (TSX-VENTURE:IMU) a company focused on
harnessing the body's own immune system to fight cancer and other
autoimmune diseases, has received initial results from The
University of British Columbia ("UBC") screening program.
One of the three key programs BioMmune is currently working on
at UBC is a complex screening program on a marine extract library
of compounds provided by Dr. Raymond Andersen UBC, Professor of
Chemistry, Department of Earth, Ocean & Atmospheric Sciences
and his colleagues. This library has previously yielded important
new small molecule drugs. As cancer cells transition from primary
to metastatic they continue to evolve under the negative selection
of the immune system until the cancer cell learn to hide from the
human immune system. The screen devised and developed at UBC by
Professor Wilfred Jefferies and his colleagues in UBC's, Michael
Smith Laboratory, identifies small molecules that unmasks the
metastatic forms of cancer and re-enables the body's own immune
system to attack the cancer cells.
"The development of cancer therapeutics has evolved
significantly due to the ability to diagnose cancer much earlier
than in the past. Early cancer therapeutics were for the most part,
indiscriminate and simply targeted dividing cells and thereby
killing both normal and cancerous cells. Today a more deeper
understanding of the processes leading to the emergence of cancers
have led to the development of better biologics that focus on only
selectively killing cancer cells and rendering normal cells and
tissues unharmed. The human body possesses an immune mechanism,
that already recognizes abnormal cells from normal cells and
eliminates abnormal cells, but during the course of cancer, the
cancer cells can develop an ingenious strategy to hide from the
immune system. The approach we have taken, is to unmask and restore
selective cancer recognition by the immune system. This development
project is now well advanced and provides the promise of a new
class of anti-cancer drugs," says Dr. Reinhard Gabathuler,
President of BioMmune.
"We are very pleased and excited with the initial results from
the screening program. Thus far, UBC has examined hundreds of
natural marine product extracts that are known to be rich in new
drug candidates. Five of these extracts contain compounds that show
promising activity in the screen," said Dr. Gabathuler.
"Furthermore, in several cases, we have identified the unique
chemical structures of potential drug leads and are in the process
of protecting intellectual property related to these new chemical
entities. Thus, we anticipate the development of a number of new
and proprietary anti-cancer therapeutics resulting from this
program that may provide treatments for aggressive malignancies
such as breast, prostate, colorectal and pancreatic cancers, as
well as lymphomas and lung carcinomas and skin melanomas. Our
additional programs on the development of new vaccine technologies
and the program for creating biologics to treat autoimmune diseases
are also advancing."
ABOUT BIOMMUNE
BioMmune Technologies Inc. is a biopharmaceutical company
headquartered in Vancouver, Canada. BioMmune is developing three
technologies discovered at The University of British Columbia. They
include, discovery of compounds that will be active in restoring
immune-recognition of cancer cells resulting in the body's immune
system to fight the cancer cells. A discovery relating to Calcium
Channels, whose activities regulate the concentration of calcium
(Ca) in different compartments in cells, which is very important
for the activity of cells involved in the immune system to improve
their ability to combat cancers, infections and also
autoimmunities. Furthermore, the company is pursuing the modulation
of CD74, a protein involved in the immune system and its ability to
fight foreign antigens. Finding ways or compounds that regulate its
activity will improve the immune system to combat infections,
cancers and autoimmune diseases. BioMmune trades on the TSX Venture
Exchange under the symbol "IMU".
Forward Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue",
"anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or
developments express or implied by such forward-looking statements
or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical
trials and obtaining regulatory approval to market our products,
the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could
cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially
from any future events or results expressed or implied by such
statements and information include, but are not limited to, the
risks and uncertainties that: or future products in our targeted
corporate objectives; our future operating results are uncertain
and likely to fluctuate; we may we may not be successful in either
preclinical or clinical trials and not be able to raise additional
capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be
able to establish marketing and the costs of launching our products
may be greater than anticipated; we have no experience in
commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward- looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
On Behalf of the Board of Directors
Dr. Reinhard Gabathuler, President
"Neither the TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release"
BioMmune Technologies Inc.Dr. Reinhard
GabathulerPresident(604)644.1232gaba@biommune.net
bioMmune Technologies Inc. (TSXV:IMU)
過去 株価チャート
から 5 2024 まで 6 2024
bioMmune Technologies Inc. (TSXV:IMU)
過去 株価チャート
から 6 2023 まで 6 2024